Nitrofurantoin (NIT) has long been a drug of choice in the treatment of lower urinary tract infections. Recent emergence of NIT resistant Enterobacteriaceae is a global concern. An ordinal logistic regression model based on PCR amplification patterns of five genes associated with NIT resistance (nfsA, nfsB, ribE, oqxA, and oqxB) among 100 clinical Enterobacteriaceae suggested that a combination of oqxB, nfsB, ribE, and oqxA is ideal for NIT resistance prediction. In addition, four Escherichia coli NIT-resistant mutants were in vitro generated by exposing an NIT-susceptible E. coli to varying concentrations of NIT. The in vitro selected NIT resistant mutants (NI2, NI3, NI4 and NI5) were found to have mutations resulting in frameshifts, premature/lost stop codons or failed amplification of nfsA and/or nfsB genes. The in vitro selected NI5 and the transductant colonies with reconstructed NI5 genotype exhibited reduced fitness compared to their parent strain NS30, while growth of a resistant clinical isolate (NR42) was found to be unaffected in the absence of NIT. These results emphasize the importance of strict adherence to prescribed antibiotic treatment regimens and dosage duration. If left unchecked, these resistant bacteria may thrive at sub-therapeutic concentrations of NIT and spread in the community.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.resmic.2021.103889DOI Listing

Publication Analysis

Top Keywords

in vitro selected
12
escherichia coli
8
nit
8
nit resistant
8
nit resistance
8
nfsb ribe
8
ribe oqxa
8
concentrations nit
8
resistant
5
prediction nitrofurantoin
4

Similar Publications

Article Synopsis
  • Pancreatic cancer features a dense tissue environment that hinders effective delivery of the chemotherapy drug gemcitabine, making treatment challenging.
  • A targeted drug delivery system was developed using gold nanoparticles and the anti-EGFR antibody cetuximab, combined with gemcitabine and polyethylene glycol to enhance drug delivery to pancreatic cancer and associated cells.
  • The new drug delivery system, particularly the PEGylated nanoconjugate ACG44P1000, showed improved effectiveness in reducing the viability of pancreatic cancer cells in lab tests, setting the stage for future studies on its potential to combat tumor growth and desmoplasia in living organisms.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!